주의력결핍 과잉행동장애(ADHD) : 기회 평가 및 예측(2022-2032년)

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Attention Deficit Hyperactivity Disorder (ADHD) market through 2032.

The prevalent cases of ADHD in the 7MM will increase from 21,141,036 to 21,970,997, at an annual growth rate (AGR) of 0.4% over the forecast period. The ADHD market was valued at $11.9 billion in the 2022 baseline year.

Over the 10-year forecast period, the market is projected to decline at a negative compound annual growth rate (CAGR) of 0.9%, to $10.9 billion by 2032. The major driver for this decline is patent expiry and entry of cheap generic alternatives of branded products within the forecast period. In addition, the market has been heavily affected by shortages of active pharmaceutical ingredients (APIs) of key drug classes, which are anticipated to last until 2027.

Key Highlights

• Report deliverables include a Pdf report and an Excel-based forecast model
• Forecast includes the 7 major markets (7MM)
• Forecast covers the period 2022-2032.
• 2022 base year sales within the ALS market are approximately $11.9 billion across the 7MM detailed in this report. GlobalData estimates that the ALS market will decline at a negative compound annual growth rate (CAGR) of -0.9% to $10.9 billion by the end of the forecast period.

Scope

• Overview of ADHD, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized ADHD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the ADHD market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for ADHD. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the 7MM ADHD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM ADHD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ADHD therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

• Abbreviations
• Related Reports
• Executive Summary
• Disease Overview
• Overview of ADHD
• ADHD SWOT Analysis
• Progression of ADHD
• Diagnosis and Classification of ADHD
• Epidemiology
• Diagnosed Prevalent Cases of ADHD, Men and Women, 2022-32
• Diagnosed Prevalent Cases of ADHD by Sex, 2022
• Diagnosed Prevalent Cases of ADHD by Presentation, Men and Women, 2022
• Diagnosed Prevalent Cases of ADHD by Severity, Men and Women, 2022
• Sources and Methodology: Diagnosed Prevalent Cases of ADHD
• Sources and Methodology: Diagnosed Prevalent Cases of ADHD by Presentation
• Sources and Methodology: Diagnosed Prevalent Cases of ADHD by Severity
• Current Treatment Options
• Treatment Paradigm
• Current Treatment Options
• Current Treatment Options: KOL Perspective
• Product Profile: Amphetamines (Vyvanse, Adderall, Mydayis, Dyanavel, Adzenys, Evekeo, Dexedrine, Xelstrym)
• Product Profile: Methamphetamines (Desoxyn)
• Product Profile: Methylphenidates (Concerta, Daytrana, Metadate CD, Methylin, Ritalin, Medikinet, Jornay PM, Aptensio XR, Quillivant XR, QuilliChew, Relexxii, Cotempla XR-ODT, Azstarys, Focalin)
• Product Profile: Alpha-2A Adrenergic Agonists (Intuniv; guanfacine hydrochloride ER)
• Product Profile: Noradrenergic Reuptake Inhibitors (Strattera and Qelbree)
• Unmet Needs and Opportunities
• Unmet Needs in ADHD
• Non-stimulant with a Stimulant-Comparable Efficacy Profile
• Products Providing Evening Coverage Without Sleep Disturbance
• Products Providing Dual Symptomatic Relief of Common ADHD Comorbidities
• Greater Awareness and Education of Prescribers
• R&D Strategies
• Trends in Clinical Trial Design in ADHD
• Trends in Deal-Making in ADHD
• Pipeline Assessment
• ADHD Pipeline Overview
• Late-Stage Pipeline Agents for ADHD
• Product Profile: Cingulate Inc's CTx-1301
• Product Profile: Axsome Therapeutics Inc's Solriamfetol Hydrochloride
• Product Profile: Otsuka Pharmaceutical Co's Centanafadine SR
• Product Profile: Neurocentria Inc's NRCT-101SR
• ADHD: Clinical Trials (Phase II/III) Overview
• Market Outlook
• ADHD Market Forecast
• Market Drivers and Barriers
• Market Drivers and Barriers: Global ADHD Medication Shortages

Appendix

• Primary Research: KOL Information
• Bibliography
• About the Authors
• Contact Us